DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Learn more
  • Home >
  • Research & Development

Pipeline

Our clinical development program focuses on applications of our lead product candidate, taurolidine.

Catheter Lock Solutions

HEMODIALYSIS (TAUROLIDINE + HEPARIN)

Pre-Clinical

Phase 1

Phase 2

Phase 3

Registration

Approved

ONCOLOGY (TAUROLIDINE + HEPARIN)

Pre-Clinical

Phase 1

Phase 2

Phase 3

Registration

Approved

PEDIATRIC HEMODIALYSIS (TAUROLIDINE + HEPARIN)

Pre-Clinical

Phase 1

Phase 2

Phase 3

Registration

Approved

TOTAL PARENTERAL NUTRITION (TAUROLIDINE + HEPARIN)

Pre-Clinical

Phase 1

Phase 2

Phase 3

Registration

Approved

Therapeutic Uses

ONCOLOGY - NEUROBLASTOMA

Pre-Clinical

Phase 1

Phase 2

Phase 3

Registration

Approved

Early science

See an overview of our product candidates

Learn more